在剛剛發(fā)布的2024年度業(yè)績中，復(fù)宏漢霖以連續(xù)兩年盈利的亮眼成績單（2024年?duì)I收57.24億元，凈利潤同比增長50.3%）領(lǐng)跑行業(yè)。憑借6款上市產(chǎn)品累計(jì)惠及全球75萬患者的商業(yè)化實(shí)力，我們再次印證了“創(chuàng)新”與“全球化”兩大戰(zhàn)略的高效驅(qū)動。

如今，復(fù)宏漢霖的全球化版圖已覆蓋50多個(gè)國家和地區(qū)，并持續(xù)以“聚·創(chuàng)”為核心，推動技術(shù)與生態(tài)的雙重變革。2025年，復(fù)宏漢霖將進(jìn)一步驅(qū)動創(chuàng)新引擎，在技術(shù)平臺領(lǐng)域持續(xù)突破，引領(lǐng)創(chuàng)新管線爆發(fā)式成長，積極布局前沿技術(shù)，加速為患者帶來更多可負(fù)擔(dān)的創(chuàng)新成果，實(shí)現(xiàn)從技術(shù)積淀到臨床價(jià)值的高效轉(zhuǎn)化。

值此創(chuàng)新質(zhì)變與戰(zhàn)略升級之際，復(fù)宏漢霖將于2025年4月15日在上海舉辦2025全球研發(fā)日（R&D Day）活動。

本次活動將聚焦復(fù)宏漢霖在創(chuàng)新研發(fā)領(lǐng)域的最新進(jìn)展、未來戰(zhàn)略規(guī)劃以及前沿技術(shù)、療法布局，與來自業(yè)界的頂級專家學(xué)者、創(chuàng)新研發(fā)負(fù)責(zé)人、投資人等展開深度交流。

期待您的蒞臨，共話創(chuàng)新未來！

關(guān)于復(fù)宏漢霖

復(fù)宏漢霖（2696.HK）是一家國際化的創(chuàng)新生物制藥公司，致力于為全球患者提供可負(fù)擔(dān)的高品質(zhì)生物藥，產(chǎn)品覆蓋腫瘤、自身免疫疾病、眼科疾病等領(lǐng)域，已有6款產(chǎn)品在中國獲批上市，4款產(chǎn)品在國際獲批上市，5個(gè)上市申請分別獲中國藥監(jiān)局、美國FDA和歐盟EMA受理。自2010年成立以來，復(fù)宏漢霖已建成一體化生物制藥平臺，高效及創(chuàng)新的自主核心能力貫穿研發(fā)、生產(chǎn)及商業(yè)運(yùn)營全產(chǎn)業(yè)鏈。公司已建立完善高效的全球創(chuàng)新中心，按照國際藥品生產(chǎn)質(zhì)量管理規(guī)范（GMP）標(biāo)準(zhǔn)進(jìn)行生產(chǎn)和質(zhì)量管控，不斷夯實(shí)一體化綜合生產(chǎn)平臺，其中，公司商業(yè)化生產(chǎn)基地已相繼獲得中國、歐盟和美國GMP認(rèn)證。

復(fù)宏漢霖前瞻性布局了一個(gè)多元化、高質(zhì)量的產(chǎn)品管線，涵蓋約50個(gè)分子，并全面推進(jìn)基于自有抗PD-1單抗H藥漢斯?fàn)?的腫瘤免疫聯(lián)合療法。截至目前，公司已獲批上市產(chǎn)品包括國內(nèi)首個(gè)生物類似藥漢利康?（利妥昔單抗）、自主研發(fā)的中美歐三地獲批單抗生物類似藥漢曲優(yōu)?（曲妥珠單抗，美國商品名：HERCESSI?，歐洲商品名：Zercepac?）、漢達(dá)遠(yuǎn)?（阿達(dá)木單抗）、漢貝泰?（貝伐珠單抗）、全球首個(gè)獲批一線治療小細(xì)胞肺癌的抗PD-1單抗?jié)h斯?fàn)?（斯魯利單抗，歐洲商品名：Hetronifly?）以及漢奈佳?（奈拉替尼）。公司亦同步就19個(gè)產(chǎn)品在全球范圍內(nèi)開展30多項(xiàng)臨床試驗(yàn)，對外授權(quán)全面覆蓋歐美主流生物藥市場和眾多新興市場。

In our recently released 2024 annual results, Henlius has achieved profitability for the second consecutive year, marking another milestone in our journey. With revenue reaching RMB 5.724 billion and net profit surging by 50.3% year-on-year, we continue to lead the industry. Our six approved products have now benefited over 750,000 patients worldwide, underscoring the success of our dual strategies of "Innovation" and "Globalization".

Today, Henlius' global presence spans more than 50 countries and regions, driven by our core philosophy of "Collaborate to Create". This approach has enabled us to drive technological advancements and transform the healthcare ecosystem. In 2025, we will further power our innovation engine, making continuous breakthroughsin technology platforms while fostering explosive growth in ourdifferentiatedpipeline. We arestrategically advancingcutting-edge technologies toaccelerate the delivery of more affordable and transformative solutions for patients, ensuring the efficientt transformation of technological expertise into clinical value.

As we enter a new phase of innovation and strategic evolution, we are excited to announce the 2025 Global R&D Day, to be held on April 15, 2025, in Shanghai.

This event will showcase our latest advancements in R&D, future strategic plans, and pioneering technologies and therapies. It will also serve as a platform for in-depth discussions with top industry experts, R&D leaders, investors, and other key stakeholders.

We look forward to your presence and to exploring the future of innovation together.

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 5 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI? in the U.S., Zercepac? in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly? in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What’s more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.

聯(lián)系方式

媒體：PR@Henlius.com

投資者：IR@Henlius.com

喜歡本文內(nèi)容

點(diǎn)擊下方按鈕·分享 ·收藏 ·點(diǎn)贊 ·在看